A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. The index has shown a price loss of -47.26% this year. Over the last six months, there has been a weaker performance of 55.06%. The price of ALGS leaped by -38.82% during the last 30 days period. For the last 5-days stocks have slided -17.02%.
Aligos Therapeutics Inc ‘s stock market performance has been somewhat predictable. The company’s stock reached a 1-year high price of $46.80 on 01/06/25, while the lowest value for the same period was recorded at $6.76 on 10/08/24.
52-week price history of ALGS Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Aligos Therapeutics Inc’s current trading price is -55.11% away from its 52-week high, while its distance from the 52-week low is 210.80%. The stock’s price range during this period has varied between$6.76 and $46.80. The Aligos Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.72 million for the day, a figure considerably higher than their average daily volume of 0.43 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Aligos Therapeutics Inc (ALGS) has experienced a quarterly rise of 106.18% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 75.38M and boasts a workforce of 66 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 21.66, with a change in price of +6.85. Similarly, Aligos Therapeutics Inc recorded 350,860 in trading volume during the last 100 days, posting a change of +48.38%.
ALGS’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for ALGS stands at 0.18. Similarly, the long-term debt-to-equity ratio is also 0.11.
ALGS Stock Stochastic Average
As of today, Aligos Therapeutics Inc’s raw stochastic average for the last 50 days stands at 3.19%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 5.98%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 27.45% and 34.40%, respectively.
